I. Postoperative adjuvant therapy for non-small cell lung cancer Patients with completely resected stage II-III non-small cell lung cancer are recommended for 4 cycles of postoperative adjuvant chemotherapy with a platinum-containing two-drug regimen. Stage IB patients with high risk factors can be considered for selective adjuvant chemotherapy. (High-risk factors include poorly differentiated, neuroendocrine, (except well-differentiated neuroendocrine carcinoma), vascular invasion, wedge resection, tumor diameter >4 cm, dirty pleural involvement, and inadequate lymph node dissection.) Adjuvant chemotherapy is usually started 3-4 weeks after surgery, and the patient’s physical condition needs to be basically restored to normal after surgery. Small cell lung cancer treatment A combination of chemotherapy, surgery and radiotherapy is recommended for patients with limited stage small cell lung cancer. The first-line chemotherapy regimen is EP (etoposide + platinum) or EC (pedialyte glycoside + carboplatin). Chemotherapy-based combination therapy is recommended for patients with extensive stage small cell lung cancer. First-line chemotherapy regimens recommended are EP, EC or lP regimens (cisplatin + irinotecan) or IC regimens (carboplatin + irinotecan).